# Imaging of Intravenous (IV) Combidex to Brain, Intra-cerebral Tumors and in Central Nervous System (CNS) Inflammation

> **NCT00659334** · PHASE2 · TERMINATED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 116 (actual)

## Conditions studied

- Brain Neoplasms

## Interventions

- **DRUG:** Ferumoxtran-10 (Combidex)
- **PROCEDURE:** Neurosurgery

## Key facts

- **NCT ID:** NCT00659334
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2000-08
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 116 (ACTUAL)
- **Why stopped:** AMAG not continuing with Combidex, the study drug
- **Last updated:** 2022-12-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00659334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00659334, "Imaging of Intravenous (IV) Combidex to Brain, Intra-cerebral Tumors and in Central Nervous System (CNS) Inflammation". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00659334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*